PRESS RELEASES
Archives
October 31, 2014 - OptiNose Announces Publication of Pivotal Phase III Results for Investigational Migraine Treatment Developed by OptiNose Using Bi-Directional™ Breath Powered™ Technology
August 4, 2014 - OptiNose Completes Series C-1 Financing
June 12, 2014 - OptiNose Expands Senior Management Team with Three Key Appointments in Core Business Areas of Operations, Regulatory Affairs and Commercialization
June 10, 2014 - OptiNose Announces Positive Results of COMPASS: A Head-to-Head Comparison of a New Migraine Treatment Using Bi-Directional™ Breath Powered™ Technology (AVP-825) versus Oral Sumatriptan
March 26, 2014 - OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
January 30, 2014 - New Drug Application Submitted for Migraine Treatment Using OptiNose Technology
October 31, 2013 - First Patient Enrolled in Phase III Studies Using OptiNose’s Novel Breath Powered™ Device to Deliver Fluticasone Intranasally for Treatment of Nasal Polyps
September 20, 2013 - OptiNose Partner Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal “Headache”
July 2, 2013 - Avanir Pharmaceuticals and OptiNose Announce Development and Commercialization Agreement for a New Fast-Acting Sumatriptan Investigational Product for the Treatment of Acute Migraine
June 28, 2013 - OptiNose to Present Data Highlighting New Migraine Treatment at International Headache Congress